Storm Therapeutics Research
A Phase 2 study of STC-15 in Leiomyosarcoma & Liposarcoma — targeting cancer at a deeper biological level
STC-15 Phase 2 Clinical Trial — NCT06975293
Storm Therapeutics is actively enrolling patients with leiomyosarcoma (uterine & non-uterine) and liposarcoma into this Phase 2 study of STC-15, an oral METTL3 inhibitor. Sites are open now across the US — talk to your oncologist about eligibility.
Clinical Trial for Leiomyosarcoma & Liposarcoma Patients
Because of their cell similarities
Storm Therapeutics has opened a Phase 2 study of STC-15 in leiomyosarcoma (uterine & non-uterine). STC-15 is a METTL3 inhibitor, administered as an oral tablet monotherapy to sarcoma patients. STC-15 inhibits the differentiation of aberrant stem cells that mature into leiomyosarcoma. The study is open at three sites in the US now, with many more to come.
🔬 What Makes This Trial Important?
This study is testing a completely new way of treating leiomyosarcoma — not just attacking the tumor, but trying to interrupt how the cancer forms and grows at a deeper level.
- STC-15 targets METTL3, which plays a role in how cells "decide" what they become.
- In LMS, some cells behave like abnormal stem cells, which can keep producing more cancer.
- This drug is designed to block that process, potentially slowing or stopping tumor growth at its source.
💡 In simple terms: Instead of just shrinking tumors, this approach may help stop the cancer from continually rebuilding itself.
💊 Why Patients Might Care About This Treatment
1. A New Mechanism — Different from Standard Chemo
Most LMS treatments (like doxorubicin) work by killing rapidly dividing cells. STC-15 works differently — it aims to reprogram or disrupt cancer cell development.
This could mean:
- Activity in patients who no longer respond to standard treatments
- A new option for difficult-to-treat disease
2. Oral Therapy — Pill Instead of IV
- Taken as a tablet, not an infusion
- May reduce time spent in clinics
- Potentially easier to fit into daily life
💊 For many patients, this is a meaningful quality-of-life benefit.
3. Focus on Leiomyosarcoma Specifically
- This trial includes both uterine and non-uterine LMS
- LMS has historically had limited targeted therapy options
❤️ That makes this study especially important — it is built for this patient community, not just borrowed from another cancer type.
📊 Why a Phase 2 Trial Matters
Phase 2 trials are where researchers start to answer:
- Does this drug actually work in this cancer?
- How well does it control disease?
- What are the side effects?
Positive results here can lead to:
- Larger Phase 3 trials
- Faster development timelines
- Potential future approval
🌍 Bigger-Picture Impact
If STC-15 is successful, it could:
- Open the door to a new class of drugs — METTL3 inhibitors
- Change how LMS is treated — shifting toward targeting cancer biology, not just tumor size
- Provide hope for more personalized and less toxic treatments
❤️ What Patients Should Realistically Keep in Mind
- This is still early-stage research
- We don't yet know how effective it will be
- Not everyone will benefit
🔬 But trials like this are how progress happens — especially in rare cancers like LMS.
Bottom Line — Patient Takeaway
This trial represents hope for a smarter, more targeted way to treat leiomyosarcoma — one that may go after the root of the cancer, not just the symptoms.
Learn More & Find Trial Sites
View full eligibility criteria, participating sites, and enrollment details on ClinicalTrials.gov
View Clinical Trial — NCT06975293